Acquaretici: dalla fisiologia alla clinica

Agre P. , Preston G.M. , Smith B.L. , Jung J.S. , Raina S. , Moon C. , Guggino W.B. , Nielsen S. Aquaporin CHIP: The archetypal molecular water channel. Am J Physiol 1993; 265: F463–F476.

Nielsen S. , Digiovanni S.R. , Christensen E.I. , Knepper M.A. , Harris H.W. Cellular and subcellular immunolocalization of vasopressin regulated water channel in rat kidney Proc Natl Acad Sci USA 1993; 90: 11663–7.

Nielsen S. , Kwon T.H. , Christensen B.M. , Promeneur D. , Frokiaer J. , Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647–63.

Sherlock M. , Thompson C.J. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol 2010; 162(Suppl 1): S13–8.

Schrier R.W. , Arroyo V. , Bernardi M. , Epstein M. , Henricksen J. , Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151–7.

Kim J. , Summer S. , Howard R. , Schrier R.W. Vasopressin gene expression in rats with experimental cirrhosis. Hepatology 1993; 17: 143–7.

Ivarsen P. , Frokiaer J. , Aagaard N. , Hansen E. , Bendtsen F. , Nielsen S. , Vilstrup H. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut 2003; 52: 1194–9.

Kim J.K. , Michel J.B. , Soubrier F. , Durr J. , Corvol P. , Schrier R.W. Arginine vasopressin gene expression in chronic cardiac failure in rats. Kidney Int 1990 Nov; 38(5): 818–22.

Goldsmith S.R. , Francis G.S. , Cowley A.W. Jr. . Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 1986 Aug 1; 58(3): 295–9.

Xu D. , Martin P.Y. , Ohara M. . Upregulation of aquaporin-2 water channel expression in chronic heart failure. J Clin Invest 1997; 99: 1500–05.

Funayama H. , Nakamura T. , Saito T. . Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004 Oct; 66(4): 1387–92.

Packer M. , Lee W.H. , Kessler P.D. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation 1986 Oct; 74(4): 766–74.

Decaux G. , Soupart A. , Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008 May 10; 371(9624): 1624–32.

Schrier R.W. , Gross P. , Gheorghiade M. , Berl T. , Verbalis J.G. , Czerwiec F.S. , Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatriemia. N Engl J Med 2006 Nov 16; 355(20): 2099–112.

Berl T. , Quittnat-Pelletier F. , Verbalis J.G. , Schrier R.W. , Bichet D.G. , Ouyang J. , Czerwiec F.S. ; SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatriemia. J Am Soc Nephrol 2010 Apr; 21 (4): 705–12.

Konstam M.A. , Gheorghiade M. , Burnett J.C. Jr. . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007 Mar 28; 297(12): 1319–31.

Udelson J.E. , McGrew F.A. , Flores E. . A Multicenter, randomized, placebo-controlled study on the effects of oral tolvaptan on left ventricular dilatation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007 Jun 5; 49(22): 2151–9.

Torres V.E. , Wang X. , Qian Q. , Somlo S. , Harris P.C. , Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363–4.